Business
Singapore’s National Precision Medicine (NPM) programme will partner with PacBio to propel HiFi Sequencing in Southeast Asia
This joint effort will harness PacBio's state-of-the-art HiFi sequencing technology to offer profound insights into genetic diversity, disease
About this update from Pacific Biosciences Of California, Inc.
[{"type":"text","content":"This joint effort will harness PacBio's state-of-the-art HiFi sequencing technology to offer profound insights into genetic diversity, disease mechanisms, and clinical diagnoses within Singapore’s multi-ethnic population\nSINGAPORE, Aug. 05, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced that Precision Health Research, Singapore (PRECISE) has chosen the Revio HiFi sequencing system for its Long-Read Sequencing Flagship Project. This initiative aims to generate the largest long-read sequencing dataset in Southeast Asia, marking a significant advancement for precision medicine in Singapore. As part of Singapore’s three-phase National Precision Medicine (NPM) programme, the current phase of the NPM aims to transform healthcare in Singapore and improve patient outcomes through new insights into the Asian genome. Hence, this collaboration will harness PacBio's state-of-the-art HiFi sequencing technology to offer profound insights into genetic diversity, disease mechanisms, and clinical diagnoses within Singapore’s multi-ethnic population. This partnership highlights the critical role of PacBio's HiFi sequencing technology in advancing precision medicine. Beyond the capabilities of traditional short-read sequencing technologies, PacBio's long-read sequencing provides comprehensive genomic coverage, enabling the detection of large structural variations and DNA methylation, providing a more complete picture of the genome. This multi-omics approach, combining whole genome sequencing (WGS), RNA full-length sequencing, fibre sequencing, and methylation analysis, positions PacBio as an essential contributor to the success of this joint effort with PRECISE. \"I am delighted that PRECISE has selected our Revio system for their extensive, flagship long-read sequencing project in Singapore,\" said Christian Henry, President and Chief Executive Officer of PacBio. \"PRECISE chose PacBio HiFi technology for its capacity to deliver complete and accurate genomes. This project exemplifies Revio’s unique ability to provide differentiated solutions for large-scale, multi-thousand-sample, whole genome sequencing projects.\" PacBio's joint effort with PRECISE is set to elevate precision medicine in Singapore, leveraging highly-accurate long-read sequencing to drive...